Compass Pathways Leader Of Investment Climate For Psychedelic Plays – The Daily Dive feat Jeff Stevens
Today on the Daily Dive, Jeff Stevens returns to the show to sit down with host Cassandra Leah to discuss
Read more
Psyched Wellness
Psyched Wellness Begins Pre-Clinical Trials Of Amanita Muscaria Mushroom
Psyched Wellness (CSE: PSYC) this morning announced that it has commenced its pre-clinical trials of amanita muscaria mushrooms as of
Read more
Psyched Wellness Successfully Extracts Psychedelic Mushroom
Psyched Wellness (CSE: PSYC) has successfully completed its first extraction of the amanita muscaria mushroom. The mushroom was extracted as
Read more
Psyched Wellness Completes Extraction Protocol For First Mushroom Products
Psyched Wellness (CSE: PSYC) has completed a number of milestones with regards to getting its first amanita muscaria mushroom products
Read more
Psyched Wellness Sees Positive Results From Amanita Muscaria Toxicology Report
Psyched Wellness (CSE: PSYC) has completed its toxicology assessment on that of Amanita Muscaria, the firms core focus when it
Read more
Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board
Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as of this morning. Feeney will
Read more
Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship
It appears that Professor David Nutt has a desire to become more involved with that of Psyched Wellness (CSE: PSYC).
Read more
Daily Dive: Shroom Stocks About To Fly? With Jeff Stevens, CEO Of Psyched Wellness
Today on The Daily Dive we have Jeff Stevens, CEO of Psyched Wellness (CSE: PSYC). Jeff sits down with our
Read more
Psyched Wellness To Commence Trading Today
Psyched Wellness (CSE: PSYC) is the latest mushroom issue to hit the CSE, with the company set to begin trading
Read more